Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 (COVID-19) Lower Respiratory Tract Disease in a B-cell Acute Lymphoblastic Leukemia (ALL) Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir

Emily S. Ford,William Simmons,Ellora N. Karmarkar,Leah H. Yoke,Ayodale B. Braimah,Johnnie J. Orozco,Cristina M. Ghiuzeli, Serena Barnhill,Coralynn L. Sack,Joshua O. Benditt,Pavitra Roychoudhury,Alexander L. Greninger,Adrienne E. Shapiro,Jennifer L. Hammond,James M. Rusnak, Mikael Dolsten,Michael Boeckh,Catherine Liu,Guang-Shing Cheng,Lawrence Corey

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America（2023）

引用 25|浏览21

暂无评分

摘要

A patient with B-cell acute lymphoblastic leukemia (ALL) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had persistent, progressive pneumonia with viremia after 5 months of infection despite monoclonal antibodies, intravenous (IV) remdesivir and prolonged oral steroids. Twenty days of nirmatrelvir/ritonavir and 10 days of IV remdesivir led to full recovery.

查看译文

关键词

SARS-CoV-2,nirmatrelvir,ritonavir,severe immunocompromise,persistent viral infection,emergency single use investigational new drug

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要